allogenic hematopoietic stem cell transplantation; solid organ transplantation; graft survival; European Society for Blood and Marrow Transplantation
Abstract :
[en] We conducted a questionnaire survey of the 565 European Society for Blood and Marrow Transplantation centers to analyze the outcome of allogeneic hematopoietic stem cell transplantation (alloSCT) in recipients of solid organ transplantation (SOT). We investigated 28 patients with malignant (N=22) or nonmalignant diseases (N=6), who underwent 31 alloSCT procedures: 12 after kidney, 13 after liver, and three after heart transplantation. The incidence of solid organ graft failure at 60 months after first alloSCT was 33% (95% confidence interval [CI], 16–51%) for all patients, 15% (95% CI, 2–40%) for liver recipients, and 50% (95% CI, 19–75%) for kidney recipients (p = 0.06). The relapse rate after alloSCT (22%) was low following transplantation for malignant disorders, despite advanced stages of malignancy. Overall survival at 60 months after first alloSCT was 40% (95% CI, 19–60%) for all patients, 51% (95% CI, 16–86%) for liver recipients, and 42% (95% CI, 14–70%) for kidney recipients (p = 0.39). In summary, we show that selected SOT recipients suffering from hematologic disorders may benefit from alloSCT and experience enhanced long-term survival without loss of organ function.
European Transplant Coordinators Organization. International donation and transplantation activity 2012. Available from: http://www.europeantransplantcoordinators.org.
Eurotransplant International Foundation. Annual Report 2012. Available from: http://www.eurotransplant.org.
Cattral MS, Langnas AN, Markin RS, et al. Aplastic anemia after liver transplantation for fulminant liver failure. Hepatology 1994; 20: 813-818.
Tzakis AG, Arditi M, Whitington PF, et al. Aplastic anemia complicating orthotopic liver transplantation for non-A, non-B hepatitis. N Engl J Med 1988; 319: 393-396.
Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI,. Post-transplantation lymphoproliferative disorders: Diagnosis, prognosis, and current approaches to therapy. Curr Oncol Rep 2010; 12: 383-394.
Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 2004; 104: 822-828.
Kawahara K, Storb R, Sanders J, Petersen FB,. Successful allogeneic bone marrow transplantation in a 6.5-year-old male for severe aplastic anemia complicating orthotopic liver transplantation for fulminant non-A-non-B hepatitis. Blood 1991; 78: 1140-1143.
Hadzic N, Height S, Ball S, et al. Evolution in the management of acute liver failure-associated aplastic anaemia in children: A single centre experience. J Hepatol 2008; 48: 68-73.
Trede NS, Warwick AB, Rosoff PM, Rohrer R, Bierer BE, Guinan E,. Tacrolimus (FK506) in allogeneic bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation. Bone Marrow Transplant 1997; 20: 257-260.
Yoshimi A, Nannya Y, Ueda K, et al. Successful hematopoietic stem cell transplantation from an HLA-identical sibling in a patient with aplastic anemia after HLA-haploidentical living-related liver transplantation for fulminant hepatitis. Biol Blood Marrow Transplant 2009; 15: 389-390.
Hagglund H, Winiarski J, Ringden O, Sparrelid E, Ericzon BG,. Successful allogeneic bone marrow transplantation in a 2.5-year-old boy with ongoing cytomegalovirus viremia and severe aplastic anemia after orthotopic liver transplantation for non-A, non-B, non-C hepatitis. Transplantation 1997; 64: 1207-1208.
Schechter T, Gassas A, Weitzman S, et al. Hematopoietic stem-cell transplantation following solid-organ transplantation in children. Bone Marrow Transplant 2011; 46: 1321-1325.
Perkins JL, Neglia JP, Ramsay NK, Davies SM,. Successful bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation: Long-term follow-up and outcome. Bone Marrow Transplant 2001; 28: 523-526.
Dugan MJ, Rouch DA, Akard LP, et al. Successful allogeneic bone marrow transplantation in an adult with aplastic anemia following orthotopic liver transplantation for non-A, non-B, non-C hepatitis. Bone Marrow Transplant 1993; 12: 417-419.
Perz JB, Hegenbart U, Kroeger N, Otto G, Ho AD, Dreger P,. Successful unrelated donor stem cell transplantation for advanced myelofibrosis in an adult patient with history of orthotopic liver transplantation. Haematologica 2009; 94: 594-596.
Thaunat O, Alyanakian MA, Varnous S, et al. Long-term successful outcome of sequential cardiac and allogeneic bone marrow transplantations in severe AL amyloidosis. Bone Marrow Transplant 2005; 35: 419-420.
Mangat JS, Rao K, Kingston J, Veys P, Amrolia P, Burch M,. Early pediatric anthracycline cardiotoxicity: Managed by serial heart and bone marrow transplantation. J Heart Lung Transplant 2007; 26: 658-660.
Lin RJ, Larson RA, van Besien K, Rich ES,. Allogeneic hematopoietic cell transplantation for therapy-related myeloid leukemia following orthotopic cardiac transplantation. Case Rep Hematol 2013; 2013: 140138.
Lister J, Simpson JK, deMagalhaes-Silverman MM, et al. Allogeneic peripheral blood stem cell transplant for myelodysplasia after chemotherapy for post-transplant lymphoma in a cardiac transplant recipient at 10 years. Bone Marrow Transplant 1997; 19: 943-945.
Kobbe G, Germing U, Aivado M, et al. Treatment of secondary myelodysplastic syndrome after heart transplantation with chemotherapy and nonmyeloablative stem-cell transplantation. Transplantation 2002; 74: 1198-1200.
Matthes-Martin S, Peters C, Konigsrainer A, et al. Successful stem cell transplantation following orthotopic liver transplantation from the same haploidentical family donor in a girl with hemophagocytic lymphohistiocytosis. Blood 2000; 96: 3997-3999.
Chiang KY, Lazarus HM,. Should we be performing more combined hematopoietic stem cell plus solid organ transplants ? Bone Marrow Transplant 2003; 31: 633-642.
Gray RJ,. A Class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
Gratwohl A,. The EBMT risk score. Bone Marrow Transplant 2012; 47: 749-756.
Koenecke C, Hertenstein B, Schetelig J, et al. Solid organ transplantation after allogeneic hematopoietic stem cell transplantation: A retrospective, multicenter study of the EBMT. Am J Transplant 2010; 10: 1897-1906.
Fandrich F,. Cell therapy approaches aiming at minimization of immunosuppression in solid organ transplantation. Curr Opin Organ Transplant 2010; 15: 703-708.
